• Vaccine Name: L. donovani Recombinant LdγGCS in NIV system Vaccine
• Target Pathogen: Leishmania donovani
• Target Disease: Visceral leishmaniasis
• Vaccine Ontology ID: VO_0004241
• Type: Subunit vaccine
• Status: Research
• Antigen: Recombinant Leishmania donovani gamma-glutamyl cysteine synthetase protein (LdγGCS) (Henriquez et al., 2010).
• Adjuvant: non-ionic surfactant vesicles vaccine adjuvant
  • Adjuvant name: non-ionic surfactant vesicles vaccine adjuvant
  • VO adjuvant ID: VO_0001307
• Immunization Route: Intravenous injection (i.v.)

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: The day of infection was day 0 so that vaccination occurred pre-infection on day −28 and day −14. Animals (n  =  5/treatment) were immunized with either LPS (10 ng/ml equivalent to 5 EU/ml, 1 ng/dose), LdγGCS (2 or 50 µg, used as prepared or processed to remove endotoxin), or LdγGCS incorporated into NIV (50 µg) on days −28 and −14 (Henriquez et al., 2010).
• Challenge Protocol: On day 0 immunized mice and a control group (n  =  4–10/treatment) were infected by intravenous injection (tail vein, no anaesthetic) with 1–2 × 10^7 L. donovani strain 200016 amastigotes harvested from the spleen of an infected hamster (Henriquez et al., 2010).
• Efficacy: Incorporating LdγGCS into a NIV formulation was more effective than immunization with LdγGCS alone based on its ability to induce specific antibody pre- and post-infection. However, the vesicular formulation gave a similar level of protection as immunization with LdγGCS alone (Henriquez et al., 2010).